pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 2·1 min read
save

Praxis sinks on late-stage study fail for seizure pill, halts second trial

Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational seizure medicine, and ...

Jun 2, 2026·read at Endpoints ↗

June 2, 2026 06:31 AM EDT R&D Prax­is sinks on late-stage study fail for seizure pill, halts sec­ond tri­al Elizabeth Cairns Senior biopharma journalist Prax­is Pre­ci­sion Med­i­cines has had a de­cent run over the past eight months or so, with two ma­jor clin­i­cal wins. But on Mon­day, the com­pa­ny … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
84 words · retrieved Jun 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Praxis Precision Medicines, Inc.2Sionna Therapeutics, Inc.

related stories

  • Jun 30Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOEndpoints
  • Jun 4Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drugEndpoints
  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints